Antisoma advised to restart Theragyn study

An independent safety committee "strongly recommended" that Antisoma (EASD:ASOM) continue with its Phase III study of Theragyn to treat ovarian cancer. On Monday, ASOM had said that it would delay enrollment in the trial because of data presented at the American Society of Clinical Oncology (ASCO) showing that in a study of an HMFG-1 murine monoclonal antibody similar to Theragyn, the control group had a survival advantage over the group receiving the MAb. The committee reviewed ASOM's previous Theragyn studies and the abstract presented at ASCO. ...